Literature DB >> 25901716

Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry.

Cornelia Blaich, Carsten Müller, Guido Michels, Martin H J Wiesen.   

Abstract

BACKGROUND: The non-vitamin K antagonist oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban are being administered in fixed doses without routine monitoring of anticoagulant activities. Despite this key advantage over vitamin K antagonists (VKAs), assessment of anticoagulant intensities is required in various clinical circumstances. We developed a multi-analyte approach for mass spectrometric analysis of NOACs in human plasma.
METHODS: Plasma samples were precipitated with acetonitrile. Separation was achieved by liquid chromatography using a C18 column and a gradient elution within a run time of 2.5 min. Positive electrospray ionization was used and ion transitions monitored by a triple quadrupole mass spectrometer. Stable-isotope-labeled analogues of analytes were employed as internal standards for quantitative analysis. Certified external quality control samples were obtained for external validation.
RESULTS: For all analytes, linearity could be demonstrated over the concentration range of 1-500 μg/L (R2>0.999), and the calculated limits of quantification were <1 μg/L. Results for inter- and intra-day assay precision and trueness were obtained using internal quality control samples and remained within the acceptance criterion of ±15%. External quality control samples were measured at the specified nominal values with inter- and intra-day precisions <14%. Matrix effects were fully compensated by co-eluting internal standards, which in turn did not relevantly influence ionization efficiency.
CONCLUSIONS: The method enables rapid and reliable simultaneous determination of NOAC concentrations in human plasma. It was successfully introduced into clinical practice; a case with rivaroxaban overdose is presented to exemplify the method's applicability.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25901716     DOI: 10.1515/cclm-2014-1108

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  4 in total

Review 1.  Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.

Authors:  Steen Husted; Freek W A Verheugt; Willemijn J Comuth
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

2.  Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.

Authors:  Martin H J Wiesen; Cornelia Blaich; Max Taubert; Veronika Jennissen; Thomas Streichert; Roman Pfister; Guido Michels
Journal:  Eur J Clin Pharmacol       Date:  2018-01-28       Impact factor: 2.953

3.  UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

Authors:  Joachim Kuhn; Tatjana Gripp; Tobias Flieder; Marcus Dittrich; Doris Hendig; Jessica Busse; Cornelius Knabbe; Ingvild Birschmann
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

4.  Reversal agents of non-vitamin K dependent anticoagulants: a rapid review of the changing horizon.

Authors:  Supreet Kaur; Abhishek Kumar; Robert G Lerner; Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2016-08-25       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.